

Supplemental 2024 quarterly revenue information

Recast (\$K)	Q1 2024	Q2 2024	Q3 2024	Q4 2024	FY 2024
Total Revenue	168,491	177,235	191,476	201,814	739,016
Oncology	125,748	130,269	141,197	145,613	542,827
Biopharma & Data	37,587	43,933	46,547	49,512	177,579
Screening	-	-	1,003	4,121	5,124
Licensing & Other	5,156	3,033	2,729	2,568	13,486

As Reported (\$K)	Q1 2024	Q2 2024	Q3 2024	Q4 2024	FY 2024
Total Revenue	168,491	177,235	191,476	201,814	739,016
Precision Oncology	156,229	166,518	180,604	184,585	687,936
Clinical Test Revenue	125,748	130,269	141,197	145,613	542,827
Biopharma Test Revenue	30,481	36,249	39,407	38,972	145,109
Development Services & Other	12,262	10,717	10,872	17,229	51,080